The present invention relates to a method and system for selecting a uterine contraction inhibiting agent on the basis of protein damage information on each individual, by using individual genome base sequence analysis. The method and system according to the present invention, as a technology that can predict the side effects or danger of certain drugs (i.e., uterine contraction inhibiting agents) for each individual through sequence analyses of gene exon regions that code for various proteins that participate in the pharmacodynamics or pharmacokinetics of uterine contraction inhibiting agents, is a general-purpose technology that is not only highly reliable but also has a wide range of applications.